LDLR and systemic lupus erythematosus: In an animal model of LDL receptor knockout (LDLr-/-) mouse prone to develop SLE, MMF decreased the size of atherosclerotic lesions and reduced the population of CD4+ T lymphocytes both in the atheromatous lesion and in the periphery, which was not demonstrated in the control group with atorvastatin [122].